FDA News Release - FDA approves first biosimilar for the treatment of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

The FDA granted approval of Mvasi to Amgen, Inc. Avastin was approved in February 2004 and is manufactured by Genentech, Inc.

Mvasi is approved for the treatment of adult patients with certain colorectal, lung, brain, kidney and cervical cancers.

 

And now the end is near.. The final Bell, the final curtain.... But more much more than this I did it Bills way....